Recent advances in drug delivery and formulation最新文献_第5页

Tertiary Nanosystem Composed of Graphene Quantum Dots, Levofloxacin and Silver Nitrate for Microbiological Control. 由石墨烯量子点、左氧氟沙星和硝酸银组成的三级纳米系统用于微生物控制。

Recent advances in drug delivery and formulation Pub Date : 2022-01-01 DOI: 10.2174/2667387816666220715121107

Thamires Oliveira Vieira, Eduardo Ricci-Junior, Aline Oiveira da Silva de Barros, Luciana Magalhães Rebelo Alencar, Marcia Regina Spuri Ferreira, Terezinha de Jesus Andreoli Pinto, Ralph Santos-Oliveira, Diego de Holanda Saboya Souza

{"title":"Tertiary Nanosystem Composed of Graphene Quantum Dots, Levofloxacin and Silver Nitrate for Microbiological Control.","authors":"Thamires Oliveira Vieira, Eduardo Ricci-Junior, Aline Oiveira da Silva de Barros, Luciana Magalhães Rebelo Alencar, Marcia Regina Spuri Ferreira, Terezinha de Jesus Andreoli Pinto, Ralph Santos-Oliveira, Diego de Holanda Saboya Souza","doi":"10.2174/2667387816666220715121107","DOIUrl":"https://doi.org/10.2174/2667387816666220715121107","url":null,"abstract":"Background: Infectious diseases have the highest mortality rate in the world and these numbers are associated with scarce and/or ineffective diagnosis and bacterial resistance. Currently, with the development of new pharmaceutical formulations, nanotechnology is gaining prominence.Methods: Nanomicelles were produced by ultrasonication. The particle size and shape were evaluated by scanning electron microscopy and confirmed by dynamic light scattering, also thermogravimetric analysis was performed to evaluate the thermal stability. Finally, antibacterial activity has been performed.Results: The results showed that a rod-shaped nanosystem, with 316.1 nm and PDI of 0.243 was formed. The nanosystem was efficient against Staphylococcus aureus, Pseudomonas aeruginosa, and Bacillus subtilis subsp. spizizenii with MIC inferior to 0.98 and a synergistic effect between silver graphene quantum dots and levofloxacin was observed.Conclusion: The nanosystem produced may rise as a promising agent against the bacterial threat, especially regarding bacterial resistance.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":"234-240"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40534448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing and Evaluating the Transdermal Permeation of Hydrocortisone Transfersomes Formulation Based on Digital Analysis of the In Vitro Drug Release and Ex Vivo Studies. 基于体外释药和离体研究的氢化可的松转移体处方透皮渗透优化与评价。

Recent advances in drug delivery and formulation Pub Date : 2022-01-01 DOI: 10.2174/2667387816666220608115605

Asmae Abdelwahd, Bazigha K Abdul Rasool

{"title":"Optimizing and Evaluating the Transdermal Permeation of Hydrocortisone Transfersomes Formulation Based on Digital Analysis of the In Vitro Drug Release and Ex Vivo Studies.","authors":"Asmae Abdelwahd, Bazigha K Abdul Rasool","doi":"10.2174/2667387816666220608115605","DOIUrl":"https://doi.org/10.2174/2667387816666220608115605","url":null,"abstract":"Background: Transfersomes can be used to enhance transdermal drug delivery due to their flexibility and ability to incorporate various molecules. For example, hydrocortisone (HC), a corticosteroid, is taken by different routes and serves as immunosuppressive, anticancer, and antiallergenic; however, it is poorly absorbed by the skin.Objective: Therefore, the current study suggested HC-loaded transfersomes as an alternative route of administration for reaching deeper skin layers or systemic circulation, to reduce the side effects of HC and improve its bioavailability.Methods: HC transfersomes were prepared by the thin-film hydration method and characterized for their vesicular size, zeta potential, drug entrapment efficiency, elasticity, FTIR spectroscopy, in vitro drug release, ex vivo permeation, and irritancy in rabbits. The optimized formulation, F15 (containing HC 20 mg, egg phosphatidylcholine (EPC) 400 mg, and 75 mg of Span 80), was chosen because it showed the highest (p< 0.05) EE% (60.4±0.80) and optimized sustained in vitro drug release (Q8 = 87.9±0.6%).Results: Extensive analysis of the drug release data from all formulas was performed using the DDSolver software which quantitatively confirmed the successful formulation. The Weibull equation was the best model to fit the release data compared to others, and the release mechanism was Fickian diffusion.Conclusion: The simulated pharmacokinetic parameters showed that F15 had the highest AUC, MDT, and DE. Furthermore, F15 significantly enhanced HC permeation by 12-folds compared to the control through the excised rat's skin. The skin irritancy test has proven F15 safety and skin compatibility.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":"16 2","pages":"122-144"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9474323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Fabrication and In Vitro Evaluation of Febuxostat Tablet for Obtaining Biphasic Drug Release Profile. 制作非布索坦片剂并对其进行体外评估，以获得双相药物释放谱。

Recent advances in drug delivery and formulation Pub Date : 2022-01-01 DOI: 10.2174/2667387817666221116100127

Dipika Chavda, Deepika Joshi, Vaishali Thakkar, Tejal Gandhi

{"title":"Fabrication and In Vitro Evaluation of Febuxostat Tablet for Obtaining Biphasic Drug Release Profile.","authors":"Dipika Chavda, Deepika Joshi, Vaishali Thakkar, Tejal Gandhi","doi":"10.2174/2667387817666221116100127","DOIUrl":"10.2174/2667387817666221116100127","url":null,"abstract":"Aim and objective: The primary aim of the present investigation was to adopt the concept of quality by design (QbD) for developing Febuxostat matrix tablets containing a novel combination of polyethylene oxide (PEO), pre-gelatinized starch (PGS) and lactose for obtaining biphasic drug release.Experimental: Febuxostat-containing matrix tablets were prepared by direct compression using 32 full factorial designs. The tablets were prepared with varying amounts of PEO WSR 301 to PGS and lactose to obtain the desired release pattern. The chosen responses were cumulative % drug released at 1, 6 and 12 hours. The evaluation of tablets was done for pre and post-compressional parameters. Compared with the marketed tablet, the optimized formulations were selected based on in vitro drug release. Dose dumping was checked in the dissolution medium containing up to 40% alcohol.Results and discussion: The results of the dissolution study indicated that the batch containing a 1:1 ratio of PEO WSR 301 and PGS (15 mg each) and 20 mg of Lactose showed fast initial drug release to imitate the pharmacological action followed by sustained drug release effect. The use of Lactose facilitated immediate drug release, while PEO WSR 301 and PGS exhibited the opposite effect on cumulative drug release. The results of the 32 Factorial design revealed that the concentration of Lactose is a critical parameter. Dose dumping was not observed in the alcoholic dissolution medium. Kinetic equations were fitted to the dissolution data after 1 hour of the dissolution study.Conclusion: The type (soluble or swellable) and the concentration of excipients (low or high) dictate the tablets' drug release. The study's outcome revealed that the most critical material attribute is the amount of lactose. The novel combination of PEO, PGS and lactose can bypass existing patents and give more industrial applicability.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":"317-327"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40475308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered- Dose Inhaler in the Treatment of COVID-19 Patients. 环孢素超细溶液加压计量吸入器在COVID-19患者治疗中的潜在应用

Recent advances in drug delivery and formulation Pub Date : 2022-01-01 DOI: 10.2174/2772574X12666211122113318

Touraj Ehtezazi

{"title":"The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered- Dose Inhaler in the Treatment of COVID-19 Patients.","authors":"Touraj Ehtezazi","doi":"10.2174/2772574X12666211122113318","DOIUrl":"https://doi.org/10.2174/2772574X12666211122113318","url":null,"abstract":"Introduction: Serious COVID-19 respiratory problems start when the virus reaches the alveolar level, where type II cells get infected and die. Therefore, virus inhibition at the alveolar level would help preventing these respiratory complications.Method: A literature search was conducted to collect physicochemical properties of small molecule compounds that could be used for the COVID-19 treatment. Compounds with low melting points were selected along with those soluble in ethanol, hydrogen-bond donors, and acceptors.Results: There are severe acute respiratory syndrome coronavirus inhibitors with physicochemical properties suitable for the formulation as an ultrafine pressurised metered-dose inhaler (pMDI). Mycophenolic acid, Debio 025, and cyclosporine A are prime candidates among these compounds. Cyclosporine A (hereafter cyclosporine) is a potent SARS-CoV-2 inhibitor, and it has been used for the treatment of COVID-19 patients, demonstrating an improved survival rate. Also, inhalation therapy of nebulised cyclosporine was tolerated, which was used for patients with lung transplants. Finally, cyclosporine has been formulated as a solution ultrafine pMDI. Although vaccine therapy has started in most countries, inhalation therapies with non-immunological activities could minimise the spread of the disease and be used in vaccine-hesitant individuals.Conclusion: Ultrafine pMDI formulation of cyclosporine or Debio 025 should be investigated for the inhalation therapy of COVID-19.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":"16 1","pages":"3-15"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39736848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmaceutical Lozenges: Recent Trends and Developments with an Update on Research and Patents. 药用含片:最近的趋势和发展与最新的研究和专利。

Recent advances in drug delivery and formulation Pub Date : 2022-01-01 DOI: 10.2174/2667387816666211231103759

Mangesh Pradeep Kulkarni, Arun Sharma, Sagar Tanwar, Parashara Bhattar Vandana, Sheetu Wadhwa, Gurvinder Singh, Pardeep Kumar, Rajesh Kumar

{"title":"Pharmaceutical Lozenges: Recent Trends and Developments with an Update on Research and Patents.","authors":"Mangesh Pradeep Kulkarni, Arun Sharma, Sagar Tanwar, Parashara Bhattar Vandana, Sheetu Wadhwa, Gurvinder Singh, Pardeep Kumar, Rajesh Kumar","doi":"10.2174/2667387816666211231103759","DOIUrl":"https://doi.org/10.2174/2667387816666211231103759","url":null,"abstract":"Pharmaceutical oral dosage forms are tremendously preferred by both consumers as well as pharmaceutical manufacturers owing to the plethora of benefits they offer. Lozenges (LZs) are one of the dosage forms that provide a palatable means of drug administration and have great importance with respect to their pharmaceutical applications. LZs offer additional benefits to pediatric and geriatric patients, along with people having problems associated with the gastro-intestinal tract. Dysphagia is a common problem faced by all age groups, which gives rise to the need for LZs. Moreover, the foremost merit presented by the medicated LZs includes its augmented retention time in the oral cavity that results in an enhanced bioavailability for buccal or upper gastro-intestinal disorders. Further, LZs can also be used to bypass the first-pass effect. The present review covers various aspects of LZs such as formulation, manufacturing techniques, evaluation parameters, marketed products, patents, and a compilation of research work that has been done on lozenges as a delivery system.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":"16 1","pages":"45-54"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39775379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Recent Advancements in Hyperthermia-Driven Controlled Drug Delivery from Nanotherapeutics. 纳米疗法在热疗驱动可控给药方面的最新进展。

Recent advances in drug delivery and formulation Pub Date : 2022-01-01 DOI: 10.2174/2667387816666220902091043

Mirza Shahed Baig, Mohammad Akiful Haque, Teja Kumar Reddy Konatham, Badrud Duza Mohammad, Barrawaz Aateka Yahya, Shaikh Sana Saffiruddin, Falak A Siddiqui, Sharuk L Khan

{"title":"Recent Advancements in Hyperthermia-Driven Controlled Drug Delivery from Nanotherapeutics.","authors":"Mirza Shahed Baig, Mohammad Akiful Haque, Teja Kumar Reddy Konatham, Badrud Duza Mohammad, Barrawaz Aateka Yahya, Shaikh Sana Saffiruddin, Falak A Siddiqui, Sharuk L Khan","doi":"10.2174/2667387816666220902091043","DOIUrl":"10.2174/2667387816666220902091043","url":null,"abstract":"Previous reviews of the works on magnetic nanoparticles for hyperthermia-induced treatment concentrated mostly on magnetic fluid hyperthermia (MFH) employing monometallic/metal oxide nanocomposites. In the literature, the word \"hyperthermia\" was also limited to the use of heat for medicinal purposes. A number of articles have recently been published demonstrating that magnetic nanoparticle-based hyperthermia may produce restricted high temperatures, resulting in the release of medicines that are either connected to the magnetic nanoparticles or encased in polymer matrices. In this debate, we propose broadening the concept of \"hyperthermia\" to encompass temperature-based treatment as well as magnetically controlled medication delivery. The review also addresses core-shell magnetic nanomaterials, particularly nanoshells made by stacked assembly, for the use of hyperthermia- based treatment and precise administration of drugs. The primary objective of this review article is to demonstrate how the combination of hyperthermia-induced therapy and on-demand' drug release models may lead to effective applications in personalized medicine.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":"270-286"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40345801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia. l -天冬酰胺酶治疗急性淋巴细胞白血病专利综述。

Recent advances in drug delivery and formulation Pub Date : 2021-01-01 DOI: 10.2174/1872211314666210301125843

Davi Almeida Freire, Ilana Carneiro Lisboa Magalháes, Eridan Orlando Pereira Tramontina Florean, Maria Izabel Florindo Guedes

{"title":"A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia.","authors":"Davi Almeida Freire, Ilana Carneiro Lisboa Magalháes, Eridan Orlando Pereira Tramontina Florean, Maria Izabel Florindo Guedes","doi":"10.2174/1872211314666210301125843","DOIUrl":"https://doi.org/10.2174/1872211314666210301125843","url":null,"abstract":"L-asparaginase (L-asparagine amino hydrolase, E.C.3.5.1.1) is the most important chemotherapeutic drug used in treating Acute Lymphocytic Leukemia (ALL), decreasing blood asparagine rates causing apoptosis in tumor cells. However, pharmacological drugs cause several side effects making treatments difficult. Thus, searches for new sources of L-asparaginase or enzyme modifications focus on discovering new products to use in therapy. This article reviewed published patents from 2000 to 2020 related to the treatment of ALL using L-asparaginase. Many organisms have been shown as potential viable L-asparaginase producers for use in the treatment of ALL. However, this patent review shows that few of these organisms are gaining attention to becoming bioproducts for the market. It is expected that drugs in the testing phase and patents related to the treatment of ALL and other cancers will become real products. Besides, a treatment using an amino acid depletion approach, now referring to asparagine, altogether with a compound that directly interferes with the expression of the asparagine synthase gene, is more suitable for the treatment of ALL and possibly to other cancers.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":"15 1","pages":"37-45"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25448602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review. HPMC-制药行业的奇迹聚合物专利审查。

Recent advances in drug delivery and formulation Pub Date : 2021-01-01 DOI: 10.2174/1872211314666210604120619

Kumar Guarve, Priyanka Kriplani

{"title":"HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review.","authors":"Kumar Guarve, Priyanka Kriplani","doi":"10.2174/1872211314666210604120619","DOIUrl":"https://doi.org/10.2174/1872211314666210604120619","url":null,"abstract":"At the present time, designing of defined release dosage forms, either controlled, sustained, modified, are gaining much importance. For the development of such delivery systems, proper blend of polymers is required so that drug release occurs by polymer erosion, swelling, diffusion/ dissolution. HPMC (Hydroxypropyl Methylcellulose) is the most commonly used cellulosic polymer available in various grades to develop such types of systems. Depending upon the molecular weight and viscosity chosen, it can be applied for emulsification, adhesion, bonding, thickening, suspension, film forming and gelation. It consists of polymeric units linked together, which retain water, thereby acting as an excellent hydrophilic gel forming polymer. It generally hydrates on the outer surface to form a gelatinous layer. It swells, expands upon contact with water and releases the drug in predetermined manner initially and then forms viscous gel to control the release further. The objective of the present review is to overview the recent patents and articles of HPMC, its properties, grades and its use in various drug delivery systems and as a binder, dispersing agent, bioavailability enhancer and as capsule forming material have been identified and reviewed.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":"15 1","pages":"46-58"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39077344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations. 仿制药的共晶:固体口服剂量制剂的展望。

Recent advances in drug delivery and formulation Pub Date : 2021-01-01 DOI: 10.2174/2667387815666210203151209

Maniyam Arun Pandian Rajendran, Ravikiran Allada, Syed Shahnawaz Sajid

引用次数: 8

An Overview of Recent Patents and Patented Technology Platforms Based on Co-Processed Excipients. 基于共加工赋形剂的最新专利和专利技术平台综述。

Recent advances in drug delivery and formulation Pub Date : 2021-01-01 DOI: 10.2174/1872211314999210104211125

Deepak Kaushik, Etisha Goel, Ravinder Verma, Parijat Pandey, Deepika Purohit, Vineet Mittal, Kuldeep Kumar, Md Habibur Rahman

{"title":"An Overview of Recent Patents and Patented Technology Platforms Based on Co-Processed Excipients.","authors":"Deepak Kaushik, Etisha Goel, Ravinder Verma, Parijat Pandey, Deepika Purohit, Vineet Mittal, Kuldeep Kumar, Md Habibur Rahman","doi":"10.2174/1872211314999210104211125","DOIUrl":"https://doi.org/10.2174/1872211314999210104211125","url":null,"abstract":"Background: There is no single-component excipient that fulfills all the requisite performance to allow an active pharmaceutical ingredient to be formulated into a specific dosage form. Co-processing is a novel concept that incorporates a combination of two or more excipients, that is advantageous and cannot be achieved using a physical admixture.Objective: This review provides an overview of co-processed excipients, recent patents granted and filed in this field and the commercial patented technology platforms based on these excipients.Methods: Various online patent databases were used for collecting the information on recent patents and patented co-processed excipient technologies. The recent patents such as single-step coprocessing by dry coating, novel co-processed excipients for oily drugs and novel silica-coated compositions have been discussed.Results: Co-processed excipients are evolving as a current and future trend of excipient technology in pharmaceutical manufacturing, which is evident by the increasing number of patents based on these excipients. Among various techniques, the maximum number of patents is based on the spray drying technique.Conclusion: In this work, the authors have focussed on recent patents and commercial technologies on co-processed excipient. A better understanding of this will help researchers and pharmaceutical industries to select the appropriate platform, or to develop new innovative co-processed excipients with improved tableting characteristics.","PeriodicalId":20955,"journal":{"name":"Recent advances in drug delivery and formulation","volume":"15 1","pages":"3-14"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38779701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2